Abstract
Global drug pricing is one of the most hotly debated yet least understood topics in healthcare. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved? Should they? How can a life-saving industry have a poorer reputation than gun and tobacco industries, whose products are associated with death?
Access to healthcare is considered a fundamental right by many. But how can we make much needed drugs available across the world, with vastly different affordability between and within countries? Patients in Africa have severe struggles in getting access to anti-cancer drugs, but the same may be true for some populations in the United States or England.
How do we secure patient access to the many new innovative technologies that improve lives, but also ensure venture capital and big pharma investment in scientifically complex and expensive technology? A drug that stays on the pharmacy shelf does not help a patient, but neither does a patent without development investment.
Ed Schoonveld will describe critical considerations in the drug pricing process and explore solutions for improving patient access at affordable prices . Ed has deep expertise in global pricing and reimbursement, both in Europe and in the US. Ed has had tenures at corporate headquarters as the leader of global pricing and health economics groups in Wyeth, Eli Lilly and BMS and, as a consultant, has advised most large drug companies on product pricing, market access strategy, and global pricing policy. He is the author of The Price of Global Health: Strategies to Balance Patient Access and the Funding of Innovation.
Biography
Ed Schoonveld has deep expertise in Global Access and Pricing including his time at corporate headquarters as the leader for global pricing and health economics groups at Wyeth, Eli Lilly and BMS. He is the author of The Price of Global Health, a highly regarded book about global drug pricing and market access topics, now in its 3rd Edition.
At ZS Associates, Ed founded the Value & Access Practice which provides consulting and research on value, access and pricing, and health economics and outcomes research.
Ed previously led consulting practices in Cambridge Pharma/IMS, Analytica International and his own consultancy. He has advised most large drug companies on product pricing and market access strategy, global pricing policy, clinical and outcomes trial design and internal organizational and process challenges. Ed is a frequent speaker, writer and moderator at industry and client meetings.
Ed holds a master’s degree in Engineering from the Delft Technical University in The Netherlands, and an M.B.A. from the UCLA Anderson School of Management in Los Angeles, CA.
Guest Policy
Guests may register in advance for $15 or register at the door for $20. Please arrive at 9:30 am to check in. Advance registration opens one month before each event and closes the Wednesday before each event. There is no cost for WACHH members to attend.
